Jazz is redefining what is possible in the treatment of cancer by improving standards of care across the oncology spectrum with life-saving or life-extending therapies. As we advance our work and capabilities in oncology, we continue to focus on people for whom we can have the greatest impact.
One of the greatest areas of need we hope to positively impact is the understanding and treatment of gastroesophageal adenocarcinoma (GEA). GEA includes stomach cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. It is the fifth most frequent tumor and the third leading cause of cancer-related deaths worldwide.i
Despite the prevalence of GEA, the complex nature of these cancers has led to challenges in developing treatment options. As such, the overall prognosis for patients with GEA remains poor, with a global 5-year survival rate of less than 30 percent for gastric cancer and about 19 percent for GEA.ii To potentially help improve survival, one area we’re exploring is HER2-targeted therapies. HER2 is a protein that can overexpress in certain tumor types, including GEA, and cause cancers to grow at a faster rate.
The HER2 protein is found in all cells and plays an important role in cell growth and survival.iii When cancer cells develop with higher-than-normal levels of HER2, they are called HER2-positive. HER2-positive cancers tend to grow and spread faster than cancers that are HER2-negative, which can impact quality of life and lead to a higher likelihood of death.iii
Anti-HER2 medicines, commonly referred to as “HER2-targeted therapies,” work in a variety of ways. Some HER2-targeted therapies target HER2 receptor expression or interfere with HER2 pathway activation, while others work by blocking the HER2 receptors from receiving the growth signals in HER2-positive cancer cells, and in doing so, can slow or stop the growth of HER2-postive cancers.iii
Understanding the role of HER2 and the level of HER2-expression in cancers like GEA is a key component in improving therapy options for patients with this type of cancer, as approximately 20% of people with GEA have HER2-positivity.iv,v,vi Given that HER2 has emerged as a well-validated target for patients whose cancer displays HER2-positivity, testing for HER2-expression in patients diagnosed with GEA is critical to determining the appropriate treatment option.
As our pipeline continues to expand into new areas of development in difficult-to-treat cancers, we are focused on innovative research, including targeted therapy. Investigating our HER2-targeted bispecific antibody – which has biparatopic binding to two, non-overlapping HER2 epitopes – is a prime example of our innovative research in action, and we look forward to continuing to explore the potential of this therapy not just in GEA but across tumor types.
iGambardella V, Fleitas T, Tarazona N, Papaccio F, Huerta M, Roselló S, Gimeno-Valiente F, Roda D, Cervantes A. Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. J Clin Med. 2020 Sep 22;9(9):3049. doi: 10.3390/jcm9093049. PMID: 32971757; PMCID: PMC7564841.
iiBattaglin F, et al. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International. 2018;18(99).
iiiIqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.
ivAbrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625.
vVan Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.
viStroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.
الإبلاغ عن أثر جانبي
إذا كنت ترغب في الإبلاغ عن أثر جانبي مرتبط بالمنتجات الدوائية لشركة Jazz Pharmaceuticals، يُرجى إرسال بريد إلكتروني إلينا عبر الرابط التالي:
يُرجى تقديم أكبر قدر ممكن من المعلومات المتاحة.
تشمل المعلومات ذات الصلة ما يلي:
بتقديمك لتقريرك وتزويدنا ببيانات الاتصال الخاصة بك، فإنك تُقرّ وتوافق صراحةً على أنه يجوز لقسم السلامة الدوائية المحلي التواصل معك بغرض طلب معلومات إضافية أو توضيحات، إذا اعتُبر ذلك ضروريًا لتقييم التقرير ومتابعته.
يوضح إشعار الخصوصية الخاص بنا المتعلق باليقظة الدوائية والمعلومات الطبية وشكاوى المنتجات كيفية تعامل شركة Jazz Pharmaceuticals مع معالجة المعلومات الشخصية عند التعامل مع تقريرالأثر الجانبي الخاص بك، وهو متاح في مركز الخصوصية لدينا.
Report an Adverse Event
If you want to report a Adverse Event related to Jazz Pharmaceuticals medicinal products, then please send us an e-mail via this link:
Please provide as much available information as possible.
Relevant information includes:
By submitting your report and providing your contact details, you expressly acknowledge and agree that the local drug safety department may contact you for the purpose of requesting additional information or clarifications, should this be deemed necessary for the assessment and follow‑up of the report.
Our Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints outlines how Jazz Pharmaceuticals handles the processing of personal information when dealing with your adverse event report and is available in our Privacy Center.
